Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Jul;170(1):85-95.
doi: 10.1111/bjh.13399. Epub 2015 Apr 7.

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States

Chadi Nabhan  1 , Michelle Byrtek  2 , Ashish Rai  3 , Keith Dawson  2 , Xiaolei Zhou  4 , Brian K Link  5 , Jonathan W Friedberg  6 , Andrew D Zelenetz  7 , Matthew J Maurer  8 , James R Cerhan  8 , Christopher R Flowers  3
Affiliations
Multicenter Study

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States

Chadi Nabhan et al. Br J Haematol. 2015 Jul.

Abstract

Data from the National LymphoCare Study (a prospective, multicentre registry that enrolled follicular lymphoma (FL) patients from 2004 to 2007) were used to determine disease characteristics, treatment patterns, outcomes and prognosis for elderly FL (eFL) patients. Of 2650 FL patients, 209 (8%) were aged >80 years; these eFL patients more commonly had grade 3 disease, less frequently received chemoimmunotherapy and anthracyclines, and had lower response rates when compared to younger patients. With a median follow-up of 6.9 years, 5-year overall survival (OS) for eFL patients was 59%; 38% of deaths were lymphoma-related. No treatment produced superior OS among eFL patients. In multivariate Cox models, anaemia, B-symptoms and male sex predicted worse OS (P < 0.01); a prognostic index of these factors (0, 1 or ≥ 2 present) predicted OS [hazard ratio (95% CI): ≥ 2 vs. 0, 4.72 (2.38-9.33); 1 vs. 0, 2.63 (1.39-4.98)], with a higher concordance index (0.63) versus the Follicular Lymphoma International Prognostic Index (0.55). The index was validated in an independent cohort. In the largest prospective US-based eFL cohort, no optimal therapy was identified and nearly 40% of deaths were lymphoma-related, representing baseline outcomes in the modern era.

Keywords: chemotherapy; elderly lymphoma; elderly patients; follicular lymphoma; rituximab.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosures: C.N discloses consulting/advisory board roles for Genentech, Janssen, Celgene, Astellas, and Gilead. M.B discloses employment and stock options with Genentech. J.R.C discloses consulting/advisory roles with Genentech. K.D discloses employment and stock options with Genentech. C.R.F discloses consulting/advisory roles with Algeta, OptumRx, Biogen Idec, Genentech BioOncology, Roche, Celgene and research funding from Abbott, Celgene, Millennium/Takeda, Spectrum, Gilead, and Janssen/Pharmacyclics. J.W.F has no relevant conflict of interests to disclose. B.K.L discloses honoraria from Genentech, consulting and advisory roles with Genentech, AbbVie, Gilead, and research funding from Genentech, Millennium, Pharmacyclics, and Janssen. M.J.M has no relevant conflict of interests to disclose. A.R has no relevant conflict of interests to disclose. A.D.Z discloses consulting /advisory roles with Genentech, Celegene, Gilead, Amgen, Hospira, Reddy Laboratories and research funding from Genentech/Roche, Gilead, and BMS. X.Z is employed by RTI-HS, which has a research contract with Genentech.

Figures

Fig 1
Fig 1
(A) PFS for FL patients aged >80 years in the NLCS based on their initial treatment strategy. No specific regimen amongst these studied provided these elderly patients with a superior PFS. (B) PFS for FL patients aged >80 years in the NLCS based on anthracycline use. Anthracyclines did not improve PFS in this elderly cohort. (C) OS for patients aged >80 years based on initial treatment selection. No particular regimen improved OS in this elderly cohort. (D) OS for patients aged >80 years based on anthracycline use. Anthracyclines did not improve OS in this elderly cohort. FL, follicular lymphoma; NLCS, National LymphoCare Study; OS, overall survival; PFS, progression-free survival
Fig 2
Fig 2
(A) OS for patients aged >80 years based on FLIPI risk group. Log-rank test for group difference, P = 0·0148. (B) OS for patients aged >80 years based on the new prognostic index of B-symptoms, gender (male) and haemoglobin <120 g/l. Log-rank test for group difference, P < 0·0001. (C) OS for patients aged >80 years in the validation cohort using the SEER-Medicare database. Log-rank test for group difference, P = 0·0072. FLIPI, Follicular Lymphoma International Prognostic Index; OS, overall survival; SEER, Surveillance, Epidemiology and End Results
See this image and copyright information in PMC

References

    1. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110:29–36. - PubMed
    1. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504–1508. - PubMed
    1. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. Journal of Clinical Oncology. 2007;25:1824–1831. - PubMed
    1. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of Clinical Oncology. 2009;27:4555–4562. - PubMed
    1. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology. 2005;23:8447–8452. - PubMed

Publication types

LinkOut - more resources